# Pharmacological Enhancement of Glymphatic Function in Humans

> **NCT07432997** · PHASE1,PHASE2 · COMPLETED · sponsor: **Applied Cognition** · enrollment: 31 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Dexmedetomidine
- **DRUG:** Dexmedetomidine and Midodrine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07432997
- **Lead sponsor:** Applied Cognition
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-11
- **Primary completion:** 2024-09-13
- **Final completion:** 2024-09-13
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07432997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07432997, "Pharmacological Enhancement of Glymphatic Function in Humans". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07432997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*